FOGSI FDMSE Publications

Issue

FDMSEC Insights 02 - Biosimilars, Generics and Brand Confusion

This issue clarifies biosimilars, tender drugs, and market brands, with practical guidance on medicine storage, handling, traceability, and consistent implementation of regulatory requirements in clinical practice.

64 pages Feb 1, 2026
FDMSEC Insights 02 - Biosimilars, Generics and Brand Confusion cover

Read page by page

Open any page at full size. This view remains available when the interactive reader cannot load.

Cover Cover Page 001 Page 001 Page 002 Page 002 Page 003 Page 003 Page 004 Page 004 Page 005 Page 005 Page 006 Page 006 Page 007 Page 007 Page 008 Page 008 Page 009 Page 009 Page 010 Page 010 Page 011 Page 011 Page 012 Page 012 Page 013 Page 013 Page 014 Page 014 Page 015 Page 015 Page 016 Page 016 Page 017 Page 017 Page 018 Page 018 Page 019 Page 019 Page 020 Page 020 Page 021 Page 021 Page 022 Page 022 Page 023 Page 023 Page 024 Page 024 Page 025 Page 025 Page 026 Page 026 Page 027 Page 027 Page 028 Page 028 Page 029 Page 029 Page 030 Page 030 Page 031 Page 031 Page 032 Page 032 Page 033 Page 033 Page 034 Page 034 Page 035 Page 035 Page 036 Page 036 Page 037 Page 037 Page 038 Page 038 Page 039 Page 039 Page 040 Page 040 Page 041 Page 041 Page 042 Page 042 Page 043 Page 043 Page 044 Page 044 Page 045 Page 045 Page 046 Page 046 Page 047 Page 047 Page 048 Page 048 Page 049 Page 049 Page 050 Page 050 Page 051 Page 051 Page 052 Page 052 Page 053 Page 053 Page 054 Page 054 Page 055 Page 055 Page 056 Page 056 Page 057 Page 057 Page 058 Page 058 Page 059 Page 059 Page 060 Page 060 Page 061 Page 061 Page 062 Page 062 Page 063 Page 063